Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector
Inoculation with Epstein-Barr virus (EBV) induces malignant lymphomas in the cottontop tamarin (Saguinus oedipus oedipus). This provides an experimental animal model for assessing the efficacy of candidate EBV vaccines which are intended to reduce the incidence of human tumours associated with EBV infection. Previous work has shown that experimental vaccines based on the major virus envelope glycoprotein gp340 prepared from the membranes of EBV-infected cells are effective in protecting cottontop tamarins against EBV-induced disease. However, not all purified gp340 preparations induce protective immunity against EBV lymphoma in the tamarin. In this work, cottontop tamarins were immunized with recombinant gp340, produced using a bovine papillomavirus (BPV) expression vector, and a threonyl muramyl dipeptide adjuvant formulation. Although the recombinant-derived gp340 lacked the membrane anchor sequence of authentic gp340 and was expressed in mouse cells, it was immunogenic and induced virus-neutralizing antibodies. Healthy vaccinated tamarins were protected against EBV-induced disease. The demonstration that a recombinant gp340 product is able to elicit protective immunity in the cottontop tamarin is a significant step in the development of an EBV vaccine because previously it had not been clear whether a recombinant product would have the exact tertiary structure, including the necessary carbohydrate components, to induce protective immunity. A recombinant gp340 vaccine offers various advantages over production of the authentic molecule by laborious biochemical separation, including lower cost and the absence of potentially oncogenic EBV DNA. Therefore, recombinant gp340 produced using the BPV expression vector is suitable for development as a candidate EBV vaccine for a human Phase I trial and beyond.
AllisonA. C.,
ByarsN. E.1986; An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and cell mediated immunity. Journal of Immunological Methods 95:157–168
ClearyM. L.,
EpsteinM. A.,
FinertyS.,
DorfmanR. F.,
BornkammG. W.,
KirkwoodJ. K.,
MorganA. J.,
SklarJ.1985; Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 228:722–724
ConwayM.,
MorganA.,
MackettM.1989; Expression of Epstein Epstein–Barr Barr virus membrane antigen gp340/220 in mouse fibroblasts using a bovine papillomavirus vector. Journal of General Virology 70:729–734
DavidE. M.,
MorganA. J.1988; Efficient purification of Epstein Epstein–Barr Barr virus membrane antigen gp340 by fast protein liquid chromatography. Journal of Immunological Methods 108:231–236
De SchryverA.,
KleinG.,
HenleW.,
HenleG.1974; EB virus-associated antibodies in Caucasian patients with carcinoma of the nasopharynx and in long-term survivors after treatment. International Journal of Cancer 13:319–325
EminiE. A.,
SchleifW. A.,
ArmstrongM. E.,
SilberklangM.,
SchultzL. D.,
LehmanD.,
MaigetterR. Z.,
QualtiereL. F.,
PearsonG. R.,
EllisR. W.1988; Antigenic analysis of the Epstein–Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine. Virology 166:387–393
EminiE. A.,
SchleifW. A.,
SilberklangM.,
LehmanD.,
EllisR. W.1989; Vero cell-expressed Epstein Epstein–Barr Barr virus (EBV) gp350/220 protects marmosets from EBV challenge. Journal of Medical Virology 27:120–123
EpsteinM. A.,
RandleB. J.,
FinertyS.,
KirkwoodJ. K.1986; Not all potently neutralizing, vaccine-induced antibodies to Epstein–Barr virus ensure protection of susceptible experimental animals. Clinical and Experimental Immunology 63:485–490
FingerothJ. D.,
WeisJ. J.,
TedderT. F.,
StromingerJ. L.,
BiroP. A.,
FearonD. T.1984; Epstein–Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of Sciences, U.S.A. 81:4510–4514
MorganA. J.,
EpsteinM. A.1989; Prospects of immunization against EB virus. In Recent Developments in Prophylactic Immunization pp 243–254 Edited by
ZuckermanA. J.
London: Kluwer Academic;
MorganA. J.,
FinertyS.,
LovgrenK.,
ScullionF. T.,
MoreinB.1988; Prevention of Epstein–Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. Journal of General Virology 69:2093–2096
MorganA. J.,
AllisonA. C.,
FinertyS.,
ScullionF. T.,
ByarsN. E.,
EpsteinM. A.1989; Validation of a first-generation Epstein–Barr virus vaccine preparation suitable for human use. Journal of Medical Virology 29:74–78
MotzM.,
DebyG.,
WolfH.1987; Truncated versions of the two major Epstein Epstein–Barr Barr viral glycoproteins (gp250/350) are secreted by recombinant Chinese hamster ovary cells. Gene 58:149–154
PitherR. J.,
ZhangC. X.,
WallaceL. E.,
RickinsonA. B.,
MorganA. J.1991; Mapping of B and T cell epitopes on the Epstein–Barr major envelope glycoprotein gp340. In Vaccines91 pp 197–201 Edited by
LernerR. A.,
GinsbergH.,
ChanockR. M.,
BrownF.
New York: Cold Spring Harbor Laboratory;
SchultzL. D.,
TannerJ.,
HofmannK. J.,
EminiE. A.,
CondraJ. H.,
JonesR. E.,
KieffE.,
EllisR. W.1987; Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein Epstein–Barr Barr virus. Gene 54:113–123
WhangY.,
SilberklangM.,
MorganA.,
MunshiS.,
LennyA. B.,
EllisR. W.,
KieffE.1987; Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells. Journal of Virology 61:1796–1807
Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector